Castrate-resistant Prostate Cancer Market Trends
Castrate-resistant Prostate Cancer Market |
Market Overview:
Prostate
cancer is a prevalent form of cancer affecting men's prostate gland.
Castrate-resistant prostate cancer (CRPC) is an advanced form in which cancer
still grows despite reducing testosterone levels. Treatment for CRPC includes
chemotherapy, hormone therapy, immunotherapy, radiotherapy which reduces risk
of painful symptoms.
Market key trends:
One of the key market trends is the approvals of new generation drugs. The
FDA and EMA bodies have approved several new treatment options like Abiraterone
acetate and Enzalutamide which have significantly improved survival rates in
CRPC patients. These novel drugs provide alternatives to conventional docetaxel
chemotherapy and represent a paradigm shift in treatment. They have witnessed
strong uptake post approval and are major revenue generators for companies.
This has propelled market growth of CRPC over past decade.
Segment
Analysis
The
Castrate-resistant Prostate Cancer (CRPC) market can be segmented by drug class
into chemotherapy, hormonal therapy, immunotherapy, and radiation therapy.
Hormonal therapy accounts for the largest market share as it is the most
preferred line of treatment after chemotherapy fails. Hormonal therapy drugs
Zytiga and Xtandi dominate this segment as they result in median survival rates
above 18 months.
Key Takeaways
The global Castrate-Resistant
Prostate Cancer Market is expected to witness high growth, exhibiting a
CAGR of 8.2% over the forecast
period from 2023 to 2030, due to
increasing prevalence of prostate cancer across the world.
Market size
The global Castrate-resistant Prostate Cancer market size is expected to
reach US$ 9.5 Bn in 2021 and is
projected to reach over US$ 18.7 Bn
by 2030. This growth is attributed to the rising geriatric population globally
which is more prone to develop prostate cancer.
Regional analysis
North America dominates the global CRPC market led by increasing research
funding from both private and public sources in the US. Europe holds the second
largest market share led by countries like Germany, France and the UK. The Asia
Pacific region is expected to be the fastest growing market led by improving
healthcare infrastructure and increasing awareness about prostate cancer in
countries like China and India.
Key players
Key players operating in the Castrate-resistant Prostate Cancer market are
Sanofi, Johnson & Johnson Services Inc., Pfizer Inc., Astellas Pharma Inc.,
Bayer AG, Bristol Myers Squibb, Merck Sharp & Dohme, Novartis International
AG, Eli Lilly & Company, and AstraZeneca plc. Sanofi and Johnson &
Johnson Services Inc. are the market leaders due to their wide portfolio of
CRPC drugs like Zytiga and Erleada respectively.
Read More:
https://www.dailyprbulletin.com/the-castrate-resistant-prostate-cancer-treatment-landscape/
Comments
Post a Comment